SphygmoCor update.
Why Brian Schaechter left CDX isn't so important as why he has come back:This month, we are highlighting the pivotal roles of vascular biomarkers in clinical trials. Central blood pressure and arterial stiffness parameters can serve as key endpoints in a wide range of clinical trials, beyond just those related to cardiovascular health. By offering precise measurements of heart and arterial function, these parameters enable the evaluation of therapeutic interventions across various conditions, facilitating a deeper understanding of treatment effects on the body's central circulatory system.
To support our customers with their clinical trial efforts, we are thrilled to welcome Brian Schaechter to our team.
Brian is a returning team member who spearheaded many of our clinical trial initiatives in the past. He brings a wealth of experience in clinical trial design and execution, ensuring that our collaborations and services continue to meet the high standards our customers expect.
With Brian's expertise, we are poised to enhance our support for innovative research that can lead to groundbreaking discoveries and improvements in patient care.
Add to My Watchlist
What is My Watchlist?
